Aligos Therapeutics to Present at Investor Conferences in October
Aligos Therapeutics, a clinical stage biopharmaceutical company focused on liver and viral diseases, has announced its participation in two upcoming investor conferences in October. The company will be featured in fireside chats at the following events:
1. H.C. Wainwright 8th Annual MASH Virtual Conference on October 7, 2024, at 3:00pm ET/12:00pm PT
2. H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on October 8, 2024, at 3:00pm ET/12:00pm PT
Both events will be webcast live and can be accessed through the Presentation & Events section on the Investors page of Aligos' website. Replays will be available for at least 30 days following the presentations.
Aligos Therapeutics, un'azienda biofarmaceutica in fase clinica focalizzata sulle malattie epatiche e virali, ha annunciato la sua partecipazione a due prossime conferenze per investitori che si svolgeranno a ottobre. L'azienda sarà presente in conversazioni informali durante i seguenti eventi:
1. 8ª Conferenza Virtuale Annuale MASH di H.C. Wainwright il 7 ottobre 2024, alle 15:00 ET/12:00 PT
2. 5ª Conferenza Virtuale Annuale su Epatite Virale di H.C. Wainwright l'8 ottobre 2024, alle 15:00 ET/12:00 PT
Entrambi gli eventi saranno trasmessi in diretta e saranno accessibili tramite la sezione Presentazioni & Eventi nella pagina per investitori del sito web di Aligos. Le registrazioni saranno disponibili per almeno 30 giorni dopo le presentazioni.
Aligos Therapeutics, una empresa biofarmacéutica en etapa clínica centrada en enfermedades hepáticas y virales, ha anunciado su participación en dos próximas conferencias para inversores en octubre. La compañía estará presente en charlas informales en los siguientes eventos:
1. 8ª Conferencia Virtual Anual MASH de H.C. Wainwright el 7 de octubre de 2024, a las 3:00pm ET/12:00pm PT
2. 5ª Conferencia Virtual Anual sobre Hepatitis Viral de H.C. Wainwright el 8 de octubre de 2024, a las 3:00pm ET/12:00pm PT
Ambos eventos se transmitirán en vivo y se podrán acceder a través de la sección Presentaciones & Eventos en la página para inversores del sitio web de Aligos. Las repeticiones estarán disponibles durante al menos 30 días después de las presentaciones.
Aligos Therapeutics는 간 및 바이러스 질환에 초점을 맞춘 임상 단계의 생물 제약 회사로서, 10월에 열리는 두 개의 투자자 회의에 참여한다고 발표했습니다. 이 회사는 다음 행사에서 라이브 대담에 참여할 예정입니다:
1. H.C. Wainwright 제8회 연례 MASH 가상 회의 2024년 10월 7일 오후 3시 ET/오전 12시 PT
2. H.C. Wainwright 제5회 연례 바이러스성 간염 가상 회의 2024년 10월 8일 오후 3시 ET/오전 12시 PT
두 행사 모두 실시간 웹캐스트로 방송되며, Aligos 웹사이트의 투자자 페이지에서 발표 및 이벤트 섹션을 통해 접속할 수 있습니다. 발표 후 최소 30일 동안 재생이 가능합니다.
Aligos Therapeutics, une entreprise bio-pharmaceutique en phase clinique axée sur les maladies du foie et les maladies virales, a annoncé sa participation à deux prochaines conférences pour investisseurs en octobre. L'entreprise sera présente lors de discussions informelles lors des événements suivants :
1. 8ème Conférence Virtuelle Annuelle MASH de H.C. Wainwright le 7 octobre 2024 à 15h00 ET/12h00 PT
2. 5ème Conférence Virtuelle Annuelle sur l'Hépatite Virale de H.C. Wainwright le 8 octobre 2024 à 15h00 ET/12h00 PT
Les deux événements seront diffusés en direct et pourront être consultés dans la section Présentations & Événements de la page Investisseurs du site web d'Aligos. Les rediffusions seront disponibles pendant au moins 30 jours après les présentations.
Aligos Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Leber- und Viruskrankheiten konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Oktober angekündigt. Das Unternehmen wird in informellen Gesprächen auf folgenden Veranstaltungen vertreten sein:
1. 8. Virtuelle Jahrestagung MASH von H.C. Wainwright am 7. Oktober 2024 um 15:00 Uhr ET/12:00 Uhr PT
2. 5. Virtuelle Jahrestagung zur Virushepatitis von H.C. Wainwright am 8. Oktober 2024 um 15:00 Uhr ET/12:00 Uhr PT
Beide Veranstaltungen werden live übertragen und können über den Abschnitt Präsentationen & Veranstaltungen auf der Investoren-Seite der Website von Aligos aufgerufen werden. Die Aufzeichnungen werden mindestens 30 Tage nach den Präsentationen verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will participate at two investor conferences being webcast in October:
- H.C. Wainwright 8th Annual MASH Virtual Conference
- Fireside Chat at 3:00pm ET/12:00pm PT on October 7, 2024
- H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
- Fireside Chat at 3:00pm ET/12:00pm PT on October 8, 2024
A live webcast of each event will be accessible by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at www.aligos.com. A replay of the webcasts will be available following the presentation for at least 30 days.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inzioevoke.com
FAQ
When is Aligos Therapeutics (ALGS) presenting at the H.C. Wainwright MASH Virtual Conference?
What is the date and time of Aligos Therapeutics' (ALGS) fireside chat at the H.C. Wainwright Viral Hepatitis Virtual Conference?
How can investors access the webcasts of Aligos Therapeutics' (ALGS) October 2024 investor conference presentations?
How long will the replays of Aligos Therapeutics' (ALGS) October 2024 investor conference webcasts be available?
